Article
China's Outbound Pharma Partnering Deals Gain Momentum
Aug 18, 2025

Amid persistent macroeconomic challenges and impending patent cliffs, key players in the life science industry are increasingly seeking strategic partnerships with Chinese biopharma firms to gain access to innovative products and technologies. These alliances may offer a cost-effective way for international companies to replenish pipelines and secure their future growth as well as provide Chinese firms with a revenue boost and global recognition.

Notably, 61 China-to-International partnering deals were announced in H1 2025, with 37 of those involving a US company. The aggregate total deal spend on Chinese-originated assets has also soared in recent years, reaching US$48.5 billion in the first half of 2025 compared to US$44.8 billion in the whole year of 2024.


What You'll Learn in This Article

Explore how China's biopharma sector is reshaping global dealmaking. By downloading the full article, you'll gain insights into:

  • Chinese-Originated Assets Drive Partnering Deal Values Up
    Understand the strategic shift toward backloaded partnerships and early-stage trials in China.
  • Key Partnering Deals
    Discover the top deals from 2024 and H1 2025, including billion-dollar alliances in oncology, cardiovascular, and obesity therapies.
  • Emerging Therapeutic Trends
    Learn which modalities—like GLP-1 agonists and ADCs—are attracting global investment.
  • Commercial Implications for Pharma Leaders
    See how these partnerships offer cost-effective innovation sourcing, pipeline replenishment, and accelerated global expansion.
  • Outlook
    Get expert perspectives on the future of China-to-International pharma collaborations amid geopolitical shifts.

Download the article to see the latest insights on this top, deal breakdowns, and strategic insights driving the next wave of global pharma innovation.

Related solutions

Contact Us